ReviewNeurology2010
Multiple sclerosis, vitamin D, and HLA-DRB1*15.
Review in Neurology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 97 citations in OpenAlex.
- Association between vitamin D receptor (VDR) polymorphisms and the risk of multiple sclerosis (MS): an updated meta-analysis.BMC neurology · 2019Pooled it
- Pooled it
- Difficult relationships between humans and bacteria: associations between multiple sclerosis and the human microbiome.Antonie van Leeuwenhoek · 2026Review
- Integrating Genomic, eQTL, and Mendelian Randomization Analyses to Identify Microglial Drug Targets in Multiple Sclerosis.Journal of cellular and molecular medicine · 2025Article
- Advancements in multiple sclerosis.Internal medicine journal · 2025Review
- Myelodysplastic neoplasms with repeating TAFRO syndrome-like symptoms.International journal of hematology · 2025Article
- The Canadian collaborative project on genetic susceptibility to multiple sclerosis cohort population structure and disease etiology.Frontiers in neurology · 2025Article
- Paroxysmal nocturnal hemoglobinuria with ulcerative colitis.Annals of hematology · 2023Article
- Hepatotoxicity of Drugs Used in Multiple Sclerosis, Diagnostic Challenge, and the Role of HLA Genotype Susceptibility.International journal of molecular sciences · 2023Review
- Mesenchymal stem cell therapy: A review of clinical trials for multiple sclerosis.Regenerative therapy · 2022Review
- Major histocompatibility complex (MHC) associations with diseases in ethnic groups of the Arabian Peninsula.Immunogenetics · 2021Review
- Molecular Examination of Differentially Expressed Genes in the Brains of Experimental Autoimmune Encephalomyelitis Mice Post Herceptin Treatment.Journal of inflammation research · 2021Article
- Vitamin D as a Potential Therapy for Multiple Sclerosis: Where Are We?International journal of molecular sciences · 2020Review
- Lifestyle and Environmental Factors in Multiple Sclerosis.Cold Spring Harbor perspectives in medicine · 2019Review
- Heterogeneity in association of remote herpesvirus infections and pediatric MS.Annals of clinical and translational neurology · 2018Article
- Pharmacogenomic survey of Qatari populations using whole-genome and exome sequences.The pharmacogenomics journal · 2018Article
- Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis.Nature reviews. Neurology · 2017Review
- Does the Gut Microbiota Influence Immunity and Inflammation in Multiple Sclerosis Pathophysiology?Journal of immunology research · 2017Review
- Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis.PloS one · 2016Article
- Gut microbiome and the risk factors in central nervous system autoimmunity.FEBS letters · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultiple sclerosis (MS) has a remarkable geographic distribution inversely paralleling that of regional ultraviolet radiation, supporting the hypothesis that vitamin D plays a central role in the disease etiology. The major histocompatibility complex exerts the largest genetic contribution to MS susceptibility, but much risk remains unexplained and direct gene-environment interaction is a strong candidate for this additional risk. Such interactions may hold the key for disease prevention. RECENT DEVELOPMENTS: Several recent studies strengthen the candidacy of vitamin D as a key player in the causal cascade to MS. This includes a newly identified gene-environment interaction between vitamin D and the main MS-linked HLA-DRB1*1501 allele and evidence showing that vitamin D levels are significantly lower in patients with MS as compared to controls. Also, a recent study in twins with MS supports the notion that vitamin D levels are under regulation by genetic variation in the 1alpha-hydroxylase and vitamin D receptor genes, perhaps pointing to their importance in the disease pathogenesis.
conclusionsThese findings have important practical implications for studies of disease mechanisms and prevention. Missing genetic risk may partly be explained by gene-environment interactions. More practically important is that these observations highlight a pressing need to determine if vitamin D supplementation can reduce the risk of multiple sclerosis (MS). However, the timing of action and the tissues in which this interaction takes place are not clear and future studies in prospective cohorts and animal models will be essential for deciphering the role of vitamin D in MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.